Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019

Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus

Ruth Harvey, Giada MattiuzzoComments to Author , Mark Hassall, Andrea Sieberg, Marcel A. Müller, Christian Drosten, Peter Rigsby, Christopher J. Oxenford, and study participants
Author affiliations: National Institute for Biological Standards and Control—MHRA, Potters Bar, UK (R. Harvey, G. Mattiuzzo, M. Hassall, P. Rigsby); Charité-Universitätsmedizin Berlin, Berlin, Germany (A. Sieberg, M.A. Müller, C. Drosten); German Centre for Infection Research, Berlin (M.A. Müller, C. Drosten); World Health Organization, Lyon, France (C.J. Oxenford).

Main Article

Table 4

GCV percentage (%GCV) for 5 individual serum samples in study of serologic assays for Middle East respiratory syndrome coronavirus*

Sample no. % GCV
Endpoint Potencies vs. sample 4 Potencies vs. sample 16
1 414 237 342
5 405 173 70
9 555 89 69
11 682 50 73
12 816 138 43

*Values derived from endpoint titers or from potencies expressed as relative to standard samples. GCV, geometric coefficient of variation.

Main Article

1Study participants who contributed data are listed at the end of this article.

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.